This video was produced by Stanford Medicine to highlight the success of the clinical trial for a gene therapy gel for the treatment of wounds caused by dystrophic epidermolysis bullosa (EB), a genetic condition which results in extremely fragile skin.
This gel is now marketed in the EU under the name Vyjuvek.
The video explains the basic mechanisms of the treatment, and contains perspectives from the parent of a child with dystrophic EB, and Peter Marinkovich, MD, an associate professor of dermatology, a faculty member of the program in epithelial biology and the Stanford Cancer Biology Program, who led the clinical trial.
